A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Completed · Phase 2

Conditions studied: Mycobacterium Avium-Intracellulare Infection, HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Key facts

Study ID

NCT00002170

Run by

Agouron Pharmaceuticals

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV infection
• New diagnosis of MAC bacteremia and < 7 days of therapy.
• Prior Medication:
• Allowed:
• Patients no more than 7 days of therapy for MAC disease.

You may not qualify if…

• Prior Medication:
• Excluded:
• Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.

Where it is running

• Univ of California / San Diego Treatment Ctr — San Diego, California, United States
• Harbor UCLA Med Ctr — Torrance, California, United States
• Rush Presbyterian - Saint Luke's Med Ctr — Chicago, Illinois, United States
• Boston VA Med Ctr / 151 — Boston, Massachusetts, United States
• Baylor Univ — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.